Patents by Inventor Hongran Fan
Hongran Fan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240058628Abstract: This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.Type: ApplicationFiled: September 23, 2022Publication date: February 22, 2024Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
-
Patent number: 11471708Abstract: This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.Type: GrantFiled: October 17, 2019Date of Patent: October 18, 2022Assignee: Revance Therapeutics, Inc.Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
-
Publication number: 20200345819Abstract: Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purified botulinum neurotoxin, a carrier and a viscosity modifier to one or more inner surfaces of the nose. The methods disclosed herein provide alternative methods for delivery of botulinum neurotoxin to the nasal anatomy for the treatment of rhinitis.Type: ApplicationFiled: February 11, 2019Publication date: November 5, 2020Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
-
Publication number: 20200215357Abstract: This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.Type: ApplicationFiled: October 17, 2019Publication date: July 9, 2020Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
-
Patent number: 10201594Abstract: Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purified botulinum neurotoxin, a carrier and a viscosity modifier to one or more inner surfaces of the nose. The methods disclosed herein provide alternative methods for delivery of botulinum neurotoxin to the nasal anatomy for the treatment of rhinitis.Type: GrantFiled: May 16, 2016Date of Patent: February 12, 2019Assignee: Revance Therapeutics, Inc.Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
-
Publication number: 20180214717Abstract: This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.Type: ApplicationFiled: March 27, 2018Publication date: August 2, 2018Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
-
Patent number: 9956435Abstract: This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.Type: GrantFiled: December 28, 2009Date of Patent: May 1, 2018Assignee: REVANCE THERAPEUTICS, INC.Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
-
Publication number: 20160250302Abstract: Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purified botulinum neurotoxin, a carrier and a viscosity modifier to one or more inner surfaces of the nose. The methods disclosed herein provide alternative methods for delivery of botulinum neurotoxin to the nasal anatomy for the treatment of rhinitis.Type: ApplicationFiled: May 16, 2016Publication date: September 1, 2016Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
-
Publication number: 20140120077Abstract: Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purified botulinum neurotoxin, a carrier and a viscosity modifier to one or more inner surfaces of the nose. The methods disclosed herein provide alternative methods for delivery of botulinum neurotoxin to the nasal anatomy for the treatment of rhinitis.Type: ApplicationFiled: October 28, 2013Publication date: May 1, 2014Applicant: Revance Therapeutics, Inc.Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
-
Publication number: 20110268765Abstract: This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.Type: ApplicationFiled: December 28, 2009Publication date: November 3, 2011Applicant: REVANCE THERAPEUTICS, INC.Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
-
Publication number: 20100215591Abstract: The present invention provides antimicrobial peptides that exhibit a broad range of antimicrobial activity to gram positive and gram negative bacteria, as well as fungi, mold, and virus. The antimicrobial peptide of the invention is a cationic peptide, and may contain an HIV-TAT or reverse HIV-TAT sequence, or derivative thereof. The present invention further provides antimicrobial compositions containing the cationic peptide. Such compositions are especially useful for topical application to the skin, hair, nail, vagina, urethra, ear, oral cavity, nasal passage, respiratory system, opthalmic region, and various mucosal regions. The compositions of the present invention improve the condition and/or appearance of the treated region, and are suited for long-term and/or routine use to, for example, prevent or prevent the recurrence of microbial infection. The present invention further provides kits for use in improving the condition or appearance of skin, nail, or treated area.Type: ApplicationFiled: July 28, 2008Publication date: August 26, 2010Applicant: REVANCE THERAPEUTICS, INC.Inventors: Hongran Fan Stone, Jacob M. Waugh
-
Patent number: 6087341Abstract: Skin cells are genetically altered to express a gene product encoded by an introduced polynucleotide. Specifically, the invention involves introduction of a nucleotide of interest into a skin cell by topical application of a polynucleotide that is substantially free of liposomes or charged lipids, where the skin can be either treated or untreated prior to application. Similarly, the invention involves introduction of a nucleotide of interest into a skin cell by topical application of a polynucleotide formulation comprising a liposome or charged lipid, wherein the skin is not treated by removal of hair prior to application. The method of the invention serves as a platform for delivering polynucleotides to skin cells for expression therein for any of a variety uses including, but not limited to genetic immunization.Type: GrantFiled: February 12, 1998Date of Patent: July 11, 2000Assignee: The Board of Trustees of the Leland Standford Junior UniversityInventors: Paul Khavari, Hongran Fan